Q2 FY26: Revenue up 7% to ₹2,357M, PBT grows 16% YoY on domestic recovery

Ebitda Margin ExpansionAuditor Mid Year ChangeResults View source PDF Explain this filing

SANOFICONR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹4700.30

prior close

₹4914.90

announcement price

After-mkt

timing

Nifty Microcap 250market+0.5%-0.1% vs market

Pharmaceuticals peers, median of 160sector+0.8%-0.4% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-3.1

15m

-3.3

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+0.5-0.1+0.8-0.4

Next day

-2.1-0.1-2.0+0.0-2.1

-2.1+1.0-3.0+0.1-2.1

-3.4+2.3-5.7+0.6-4.0

-3.8+2.8-6.6+1.0-4.8

-3.4+4.1-7.5+0.6-4.1

-4.0+4.5-8.5+1.6-5.6

15d

-10.0+4.8-14.8+0.5-10.5

-12.0+6.4-18.5+2.1-14.1

-17.3+5.5-22.8+4.2-21.5

-26.3-1.7-24.6-1.9-24.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 FY26 results. Revenue from operations rose 7% YoY to 2,357 million, with domestic sales up 12% aided by relaunch of recalled products (Combiflam, Allegra, Depura Kids), while exports fell 9% on a high base. H1 revenue grew 18% to 4,649 million. Q2 PBT rose 16% to 919 million and PAT grew to 688 million from 607 million. H1 PBT up 25% to 1,826 million, PAT at 1,366 million. H1 EPS at ₹59.31 versus ₹48.07. Operating cash flow for H1 jumped to 1,096 million from 179 million. Auditor Price Waterhouse issued an unmodified limited review.

Likely market impact

Strong EBITDA margin expansion, robust domestic recovery and surging operating cash flows are positives. Statutory auditor change noted but review is clean.